Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer
NCT ID: NCT00323908
Last Updated: 2023-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
281 participants
OBSERVATIONAL
2005-06-30
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
NCT00329017
Genetic Studies in Breast Cancer
NCT00582322
Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001496
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
NCT00897455
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Women at high risk for developing breast cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* willing to participate in companion protocol (KUMC HSC#4601) for random periareolar fine needle aspiration (RPFNA) for correlational studies
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alabama at Birmingham
OTHER
Avon Foundation
OTHER
National Cancer Institute (NCI)
NIH
Johns Hopkins University
OTHER
Carol Fabian, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carol Fabian, MD
Professor, Director Breast Cancer Prevention Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carol J Fabian, MD
Role: PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9933
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.